Cardinal Health raises fiscal 2027 EPS outlook after a strong first quarter
As seen on the 24/7 Wall St. homepage on November 5, 2026.
Given this quarter's strong performance and our updated expectations for the remainder of the year, we are raising our fiscal 2027 non-GAAP EPS outlook.
A guidance raise one quarter into fiscal 2027 sets a higher bar for the rest of the year at the $60.7 billion distributor, and it puts pressure on rival wholesalers reporting into the same demand backdrop. Watch how much of the raise management attributes to the quarter versus the back half.
Continue ReadingShow less
Cardinal Health CEO Jason M. Hollar announced the company is raising its fiscal 2027 non-GAAP EPS outlook, citing strong first-quarter performance alongside updated expectations for the remainder of the year. A guidance revision this early in a fiscal year is notable: it signals that management entered the period with room to spare rather than threading a needle.
For a drug distributor the size of Cardinal Health, with $60.7 billion in revenue, even modest upward revisions to earnings guidance carry weight. The scale of the business means small efficiency or demand gains compound into material dollar figures at the bottom line.
Sponsored
The more revealing question for investors is what is actually driving the raise. If the first quarter alone explains most of the lift, the back half is holding conservative assumptions that leave room for further upgrades. If management is leaning on back-half momentum to justify the new range, execution risk remains and the bar is now higher.
Rival pharmaceutical wholesalers reporting into the same demand environment will face implicit comparisons. A guidance raise by one of the sector's largest players resets expectations across the group, and any peer that simply meets prior guidance reads as a relative disappointment.
Sources
Mentioned: CAH